We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Corbus Pharmaceuticals Holdings Inc (CRBP) USD0.0001

Sell:$27.74 Buy:$28.18 Change: $0.15 (0.54%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.15 (0.54%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.15 (0.54%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company. The Company is engaged in developing and commercializing therapeutics for autoimmunity, fibrosis, and cancer. Its internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. It has developed CRB-913, a second-generation cannabinoid receptor type 1 (CB1) inverse agonist designed to treat obesity and related metabolic diseases. The CRB-913 program is in the pre-clinical-stage. It also includes Lenabasum, which is a novel, synthetic, oral molecule that selectively activates cannabinoid receptor type 2 (CB2) for the treatment of inflammation and fibrosis. Its subsidiaries include Corbus Pharmaceuticals, Inc., Corbus International Limited and Corbus Pharmaceuticals Australia Pty Ltd.

Contact details

500 River Ridge Drive
United States
+1 (617) 9630103

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$269.48 million
Shares in issue:
10.34 million
United States
US dollar

Key personnel

  • Yuval Cohen
    Chief Executive Officer, Director
  • Sean Moran
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.